Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 67

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 67
---
MedSci(9)                                    |     |              |    29,750 |     |               |       | * |
| William Fairey(10)                                               |     |              |    63,750 |     |               |       | * |
| Laurent Fischer, M.D.(11)                                        |     |              |   118,500 |     |               |       | * |
| Michael Grey(12)                                                 |     |              | 1,041,836 |     |               |  2.09 | % |
| Patrick Heron(13)                                                |     |              | 3,797,220 |     |               |  7.74 | % |
| Christopher Peetz(14)                                            |     |              | 1,717,976 |     |               |  3.41 | % |
| Peter Radovich(15)                                               |     |              |   402,411 |     |               |       | * |
| Saira Ramasastry, M.S., M.Phil.(16)                              |     |              |    42,167 |     |               |       | * |
| Joanne Quan, M.D.(17)                                            |     |              |    41,586 |     |               |       | * |
| Timothy Walbert(18)                                              |     |              |    24,084 |     |               |       | * |
| All executive officers and directors as a group (12 persons)(19) |     |              | 7,472,934 |     |               | 14.36 | % |

#### 56Mirum Pharmaceuticals2025 Proxy Statement

### TABLE OF CONTENTS
Security Ownership of Certain Beneficial Owners and Management

* Represents beneficial ownership of less than 1%.

(1) This information is based on a Schedule 13G filed with the SEC on February 14, 2025 by Janus Henderson Group plc (“Janus”). According to the Schedule 13G, as of December 31, 2024, Janus has shared power to vote or direct the vote of 4,581,642 shares of common stock and shared power to dispose or direct the disposition of 4,581,642 shares of common stock. The Schedule 13G provides information only as of December 31, 2024 and, consequently, the beneficial ownership of the above-mentioned entity may have changed between December 31, 2024 and February